What happened
India’s drugs regulator, the Central Drugs Standard Control Organization (CDSCO), approved Wegovy (semaglutide injection 2.4 mg) for a new indication: fatty liver disease. Novo Nordisk said the approval covers non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, together with a reduced-calorie diet and increased physical activity.
Background and earlier position
The release says MASH develops because excess fat accumulates in the liver, which can cause chronic inflammation and liver damage. Before this approval, Wegovy was known primarily as a weight-loss medicine based on semaglutide, a GLP-1 receptor agonist.
What changed now
Related current affairs
- Fourth India–Argentina Joint Trade Committee meeting in Buenos Aires reaffirms deepening strategic and economic partnership
- Indian Pharmacopoeia Commission holds scientific conclave on ‘Indian Pharmacopoeia (IP) 2026’ and launches phytochemical reference standards
- Regulatory and quality measures for AYUSH products: WHO-CoPP facilitation, AYUSH Standard/Quality marks, ISO work, and standardization efforts in Kerala
- FICCI-DUA White Paper projects India’s medical device industry to reach $250 billion by 2047; stresses need for maintenance ecosystem
- Sun Pharma gets Brazilian regulator nod for Semaglutide
- Dr. Reddy’s Q1 net dives 69% to ₹435.6 crore on lower revenue